Recombinant Deoxyribonuclease I Eye Drops for Ocular Graft Versus Host Disease : Results of a Randomized Clinical Trial
Copyright © 2024 Contact Lens Association of Ophthalmologists..
OBJECTIVE: We have previously shown that neutrophil extracellular traps (NETs) are present on the ocular surface of patients with ocular graft versus host disease (oGVHD), contributing to inflammation and surface disease. Therefore, we performed a clinical trial using deoxyribonuclease I (DNAase) eye drops to test the hypothesis that reducing the abundance of NETs from the ocular surface will reduce signs and symptoms of oGVHD.
METHODS: A prospective, phase I or II, randomized, placebo-controlled, double-masked clinical trial was performed to determine the safety and preliminary efficacy of DNAase (0.1%) eye drops four times daily for 8 weeks in patients with oGVHD (n=58). Intent-to-treat analysis was performed to determine the change in safety outcome measures (drug tolerability and proportion of adverse events) and efficacy outcome measures (ocular surface disease index [OSDI] score and corneal staining) between baseline and week 8.
RESULTS: Tolerability and adverse events were similar in the vehicle and DNAase groups. Within the DNAase group (but not the vehicle group), corneal staining showed a statistically significant and clinically meaningful reduction at week 8 (3.50 [2.75; 5.00]) compared with baseline (5.00 [3.00; 7.00]). The OSDI score also showed a statistically significant clinically meaningful reduction of 18.4 (9.16; 33.1) ( P <0.001) at week 8 compared with baseline (45.5 [31.8; 50.0]) within the DNAase group. The proportion of eyes that had improvement in subjective global assessment (SGA) and mucous discharge was significantly greater in the DNAase group (55.6% and 57.7% at weeks 4 and 8, respectively; P <0.0001 at both time points) as compared with the vehicle group (35.7% and 34.0% at weeks 4 and 8, respectively).
CONCLUSIONS: Treatment of patients with oGVHD using DNAase eye drops is safe and demonstrates preliminary efficacy. Deoxyribonuclease I eye drops can potentially reduce the severity of signs and symptoms of ocular surface disease in patients with oGVHD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Eye & contact lens - 50(2024), 5 vom: 01. Apr., Seite 233-240 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mun, Christine S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase I |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT02702518 Citation Status MEDLINE |
|---|
| doi: |
10.1097/ICL.0000000000001078 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368979431 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368979431 | ||
| 003 | DE-627 | ||
| 005 | 20240425232957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/ICL.0000000000001078 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM368979431 | ||
| 035 | |a (NLM)38407974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mun, Christine S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recombinant Deoxyribonuclease I Eye Drops for Ocular Graft Versus Host Disease |b Results of a Randomized Clinical Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02702518 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Contact Lens Association of Ophthalmologists. | ||
| 520 | |a OBJECTIVE: We have previously shown that neutrophil extracellular traps (NETs) are present on the ocular surface of patients with ocular graft versus host disease (oGVHD), contributing to inflammation and surface disease. Therefore, we performed a clinical trial using deoxyribonuclease I (DNAase) eye drops to test the hypothesis that reducing the abundance of NETs from the ocular surface will reduce signs and symptoms of oGVHD | ||
| 520 | |a METHODS: A prospective, phase I or II, randomized, placebo-controlled, double-masked clinical trial was performed to determine the safety and preliminary efficacy of DNAase (0.1%) eye drops four times daily for 8 weeks in patients with oGVHD (n=58). Intent-to-treat analysis was performed to determine the change in safety outcome measures (drug tolerability and proportion of adverse events) and efficacy outcome measures (ocular surface disease index [OSDI] score and corneal staining) between baseline and week 8 | ||
| 520 | |a RESULTS: Tolerability and adverse events were similar in the vehicle and DNAase groups. Within the DNAase group (but not the vehicle group), corneal staining showed a statistically significant and clinically meaningful reduction at week 8 (3.50 [2.75; 5.00]) compared with baseline (5.00 [3.00; 7.00]). The OSDI score also showed a statistically significant clinically meaningful reduction of 18.4 (9.16; 33.1) ( P <0.001) at week 8 compared with baseline (45.5 [31.8; 50.0]) within the DNAase group. The proportion of eyes that had improvement in subjective global assessment (SGA) and mucous discharge was significantly greater in the DNAase group (55.6% and 57.7% at weeks 4 and 8, respectively; P <0.0001 at both time points) as compared with the vehicle group (35.7% and 34.0% at weeks 4 and 8, respectively) | ||
| 520 | |a CONCLUSIONS: Treatment of patients with oGVHD using DNAase eye drops is safe and demonstrates preliminary efficacy. Deoxyribonuclease I eye drops can potentially reduce the severity of signs and symptoms of ocular surface disease in patients with oGVHD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 7 | |a Deoxyribonuclease I |2 NLM | |
| 650 | 7 | |a EC 3.1.21.1 |2 NLM | |
| 650 | 7 | |a Ophthalmic Solutions |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 700 | 1 | |a Surenkhuu, Bayasgalan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi-Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Atassi, Nour |e verfasserin |4 aut | |
| 700 | 1 | |a Mun, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Sheth, Tanya |e verfasserin |4 aut | |
| 700 | 1 | |a Sarwar, Monazzah Akbar |e verfasserin |4 aut | |
| 700 | 1 | |a Pradeep, Anubhav |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Sandeep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Eye & contact lens |d 2003 |g 50(2024), 5 vom: 01. Apr., Seite 233-240 |w (DE-627)NLM124671438 |x 1542-233X |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2024 |g number:5 |g day:01 |g month:04 |g pages:233-240 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/ICL.0000000000001078 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2024 |e 5 |b 01 |c 04 |h 233-240 | ||